Quick Takeaways
- TTOO - T2 Biosystems, Inc. has 17 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 17 Insiders of T2 Biosystems, Inc.
- Symbol
- TTOO on OTC
- Location
- Lexington, MA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 12 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
T2 Biosystems, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| CR Group L.P. | 10%+ Owner | $740,995 | Mixed | 09 May 2024 | ||
| GOLDMAN SACHS & CO. LLC | 10%+ Owner | $661,749 | Mixed | 24 Mar 2020 | ||
| Adrian M. Jones | Director | $661,749 | Mixed | 24 Mar 2020 | ||
| Aparna Ahuja | Chief Medical Officer | $94,500 | Mixed | 20 Feb 2022 | ||
| John McDonough | Director | $94,241 | Mixed | 01 Jul 2021 | ||
| John J. Sperzel III | Chairman, President & CEO, Director | $77,238 | Mixed | 04 Nov 2024 | ||
| Michael Terrence Gibbs | General Counsel | $29,946 | Mixed | 04 Nov 2024 | ||
| Alec Barclay | Chief Operations Officer | $28,656 | Mixed | 08 Apr 2022 | ||
| John M. Sprague | Cfo | $28,372 | Mixed | 04 Nov 2024 | ||
| Brett A. Giffin | Chief Commercial Officer | $28,362 | Mixed | 04 Nov 2024 | ||
| John W. Cumming | Director | $5,513 | Mixed | 04 Nov 2024 | ||
| David B. Elsbree | Director | $3,999 | Mixed | 04 Nov 2024 | ||
| Laura Lee Adams | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Robin Toft | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Ninfa Saunders | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Seymour Liebman | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Thierry Bernard | Director | $1,153 | Mixed | 15 Sep 2023 |
Top shareholders of T2 Biosystems, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| CR Group L.P. |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
4,732,765
mixed-class rows
|
$740,995 | — | 09 May 2024 | |
| Adrian M. Jones |
3/4/5
|
Director |
—
class O/S missing
|
4,201,582
|
$661,749 | — | 24 Mar 2020 | |
| GOLDMAN SACHS & CO. LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,201,582
|
$661,749 | — | 24 Mar 2020 | |
| Jacob Safier |
13D/G
|
Safier Jacob |
5.3%
|
1,500,000
|
$165,000 | $0 | 31 Dec 2024 | |
| JSAF Holdings, LLC |
13D/G
|
Safier Jacob |
5.3%
|
1,500,000
|
$165,000 | $0 | 31 Dec 2024 | |
| Aparna Ahuja |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
600,000
|
$94,500 | — | 20 Feb 2022 | |
| John McDonough |
3/4/5
|
Director |
—
mixed-class rows
|
598,353
mixed-class rows
|
$94,241 | — | 01 Jul 2021 | |
| John J. Sperzel III |
3/4/5
|
Chairman, President & CEO, Director |
—
mixed-class rows
|
490,400
mixed-class rows
|
$77,238 | — | 04 Nov 2024 | |
| Michael Terrence Gibbs |
3/4/5
|
General Counsel |
—
mixed-class rows
|
190,135
mixed-class rows
|
$29,946 | — | 04 Nov 2024 | |
| Alec Barclay |
3/4/5
|
Chief Operations Officer |
—
class O/S missing
|
181,945
|
$28,656 | — | 08 Apr 2022 | |
| John M. Sprague |
3/4/5
|
CFO |
—
mixed-class rows
|
180,141
mixed-class rows
|
$28,372 | — | 04 Nov 2024 | |
| Brett A. Giffin |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
180,077
mixed-class rows
|
$28,362 | — | 04 Nov 2024 | |
| John W. Cumming |
3/4/5
|
Director |
—
class O/S missing
|
35,000
|
$5,513 | — | 04 Nov 2024 | |
| David B. Elsbree |
3/4/5
|
Director |
—
mixed-class rows
|
25,025
mixed-class rows
|
$3,999 | — | 04 Nov 2024 | |
| Laura Lee Adams |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
$3,938 | — | 04 Nov 2024 | |
| Ninfa Saunders |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
$3,938 | — | 04 Nov 2024 | |
| Robin Toft |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
$3,938 | — | 04 Nov 2024 | |
| Seymour Liebman |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
$3,938 | — | 04 Nov 2024 | |
| Thierry Bernard |
3/4/5
|
Director |
—
class O/S missing
|
7,322
|
$1,153 | — | 15 Sep 2023 |
Recent Insider Transactions by Companies or Individuals for T2 Biosystems, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.